AIDA: Allergy Immunotherapy based on Designed Allergens

Develop a multi-allergen immunotherapy to accelerate tolerance and minimize side effects for patients suffering from both respiratory and food allergies.

Subsidie
€ 150.000
2023

Projectdetails

Introduction

Allergy is a severe immune reaction to foreign substances known as allergens, with respiratory and food allergies affecting 30% and 10% of the global population, respectively. A high structural similarity exists between pollen and food allergens. Therefore, many people suffer from both types of allergies.

Impact of Untreated Allergies

Untreated allergies have detrimental effects on:

  • Health-related quality of life
  • Family economics
  • Work attendance

Current Treatment Approaches

Allergy is treated as a chronic disease, with a focus on reducing symptoms (e.g., antihistamines), which is cumbersome and expensive. The only existing curative treatment, allergen immunotherapy (AIT), consists of:

  1. Up to 5 years of monthly exposure to low amounts of the triggering allergen
  2. Gradual desensitization of the immune system

Unfortunately, this approach is costly for healthcare providers, and its efficacy varies, being especially low for patients allergic to multiple pollen and foodstuff sources.

Patient Participation and Challenges

Only 40% of patients choose to undergo AIT, and 20% of these terminate the treatment early due to:

  • Strong side effects
  • Lack of efficacy

Proposed Solution

We propose the development of an urgently needed AIT by:

  • Treating several allergies at once
  • Achieving tolerance faster
  • Reducing side effects

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-4-2023
Einddatum30-9-2024
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • DANMARKS TEKNISKE UNIVERSITETpenvoerder

Land(en)

Denmark

Vergelijkbare projecten binnen European Research Council

ERC Consolid...

Identification of long-term therapeutic strategy in IgE-mediated allergy by leveraging humanized models and patient samples

This project aims to identify predictive biomarkers for anti-IgE therapy response and explore mechanisms of IgE-dependent allergies to develop long-term vaccine solutions.

€ 1.999.431
ERC Advanced...

Microbiome-derived asthma and allergy protective substances for prevention

The APROSUS Project aims to characterize microbiome-derived agents to understand their protective properties against asthma and allergies, paving the way for innovative prevention strategies.

€ 2.500.000
ERC Starting...

Understanding the impact of environmental POLlution on the adaptive Immune System

This project aims to utilize advanced omics technologies to investigate the low-concentration bioactivity of PFAS chemicals and their potential role in non-communicable diseases.

€ 1.499.749
ERC Starting...

Understanding and targeting pathogenic IgG4 responses

This project aims to investigate the antigenic and environmental triggers of IgG4 autoantibody responses in autoimmune diseases, using MuSK myasthenia gravis as a model to develop targeted therapies.

€ 1.493.090
ERC Proof of...

Phototherapy treatment for long-term COVID-19 patients

This project aims to validate a UVB phototherapy protocol for treating long-COVID symptoms through a clinical trial, offering a non-invasive solution to alleviate patient suffering globally.

€ 150.000

Vergelijkbare projecten uit andere regelingen

Mkb-innovati...

Epinefrine Auto Injector innovation

Dit project onderzoekt een innovatieve, patiënt-specifieke Epinefrine Auto-Injector pen om de effectiviteit en toegankelijkheid van anafylaxiebehandeling te verbeteren.

€ 20.000
EIC Accelerator

A breakthrough active immunotherapy for the treatment of osteoarthritis

Peptinov aims to halt osteoarthritis progression through a cost-effective immunotherapy that neutralizes IL-6, with promising Phase I results leading to a Phase II trial for out-licensing readiness.

€ 2.499.999
Mkb-innovati...

PROMENADE

Dit project onderzoekt een methode voor maatwerkbehandeling van atopische dermatitis om de kwaliteit van leven van patiënten te verbeteren.

€ 20.000
Mkb-innovati...

Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker

De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.

€ 20.000
EIC Accelerator

Revolutionizing Autoimmune Therapy: Antigen Specific Immunotherapy for Rheumatoid Arthritis with Virus Nanoparticles

Diamante Società Benefit srl aims to develop a novel treatment for autoimmune diseases using virus nanoparticles to restore immune tolerance, reducing side effects compared to current therapies.

€ 2.499.999